110 related articles for article (PubMed ID: 16704196)
1. Effects of cell-permeating peptide binding on the distribution of 125I-labeled Fab fragment in rats.
Kameyama S; Horie M; Kikuchi T; Omura T; Takeuchi T; Nakase I; Sugiura Y; Futaki S
Bioconjug Chem; 2006; 17(3):597-602. PubMed ID: 16704196
[TBL] [Abstract][Full Text] [Related]
2. Distribution of immunoglobulin Fab fragment conjugated with HIV-1 REV peptide following intravenous administration in rats.
Kameyama S; Okada R; Kikuchi T; Omura T; Nakase I; Takeuchi T; Sugiura Y; Futaki S
Mol Pharm; 2006; 3(2):174-80. PubMed ID: 16579646
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and evaluation of [188Re]organorhenium-labeled antibody fragments with renal enzyme-cleavable linkage for low renal radioactivity levels.
Uehara T; Koike M; Nakata H; Hanaoka H; Iida Y; Hashimoto K; Akizawa H; Endo K; Arano Y
Bioconjug Chem; 2007; 18(1):190-8. PubMed ID: 17226973
[TBL] [Abstract][Full Text] [Related]
4. Acid wash in determining cellular uptake of Fab/cell-permeating peptide conjugates.
Kameyama S; Horie M; Kikuchi T; Omura T; Tadokoro A; Takeuchi T; Nakase I; Sugiura Y; Futaki S
Biopolymers; 2007; 88(2):98-107. PubMed ID: 17252560
[TBL] [Abstract][Full Text] [Related]
5. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination.
Wilbur DS; Chyan MK; Hamlin DK; Vessella RL; Wedge TJ; Hawthorne MF
Bioconjug Chem; 2007; 18(4):1226-40. PubMed ID: 17583925
[TBL] [Abstract][Full Text] [Related]
6. Tumor cell retention of antibody Fab fragments is enhanced by an attached HIV TAT protein-derived peptide.
Anderson DC; Nichols E; Manger R; Woodle D; Barry M; Fritzberg AR
Biochem Biophys Res Commun; 1993 Jul; 194(2):876-84. PubMed ID: 8343170
[TBL] [Abstract][Full Text] [Related]
7. Chemical design of radiolabeled antibody fragments for low renal radioactivity levels.
Arano Y; Fujioka Y; Akizawa H; Ono M; Uehara T; Wakisaka K; Nakayama M; Sakahara H; Konishi J; Saji H
Cancer Res; 1999 Jan; 59(1):128-34. PubMed ID: 9892197
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide.
Du J; Wang H; Zhong C; Peng B; Zhang M; Li B; Hou S; Guo Y; Ding J
Mol Immunol; 2008 May; 45(10):2861-8. PubMed ID: 18346788
[TBL] [Abstract][Full Text] [Related]
9. Structure of an anti-cholera toxin antibody Fab in complex with an epitope-derived D-peptide: a case of polyspecific recognition.
Scheerer P; Kramer A; Otte L; Seifert M; Wessner H; Scholz C; Krauss N; Schneider-Mergener J; Höhne W
J Mol Recognit; 2007; 20(4):263-74. PubMed ID: 17712773
[TBL] [Abstract][Full Text] [Related]
10. Renal brush border enzyme-cleavable linkages for low renal radioactivity levels of radiolabeled antibody fragments.
Akizawa H; Imajima M; Hanaoka H; Uehara T; Satake S; Arano Y
Bioconjug Chem; 2013 Feb; 24(2):291-9. PubMed ID: 23330714
[TBL] [Abstract][Full Text] [Related]
11. In vitro system to estimate renal brush border enzyme-mediated cleavage of Peptide linkages for designing radiolabeled antibody fragments of low renal radioactivity levels.
Fujioka Y; Satake S; Uehara T; Mukai T; Akizawa H; Ogawa K; Saji H; Endo K; Arano Y
Bioconjug Chem; 2005; 16(6):1610-6. PubMed ID: 16287261
[TBL] [Abstract][Full Text] [Related]
12. Distribution of KAI-9803, a novel δ-protein kinase C inhibitor, after intravenous administration to rats.
Miyaji Y; Walter S; Chen L; Kurihara A; Ishizuka T; Saito M; Kawai K; Okazaki O
Drug Metab Dispos; 2011 Oct; 39(10):1946-53. PubMed ID: 21712433
[TBL] [Abstract][Full Text] [Related]
13. Isotope-edited NMR studies of Fab'-peptide complexes.
Tsang P; Fieser TM; Ostresh JM; Lerner RA; Wright PE
Pept Res; 1988; 1(2):87-92. PubMed ID: 2980784
[TBL] [Abstract][Full Text] [Related]
14. The structure of the anti-c-myc antibody 9E10 Fab fragment/epitope peptide complex reveals a novel binding mode dominated by the heavy chain hypervariable loops.
Krauss N; Wessner H; Welfle K; Welfle H; Scholz C; Seifert M; Zubow K; Aÿ J; Hahn M; Scheerer P; Skerra A; Höhne W
Proteins; 2008 Nov; 73(3):552-65. PubMed ID: 18473392
[TBL] [Abstract][Full Text] [Related]
15. Effects of specific antibody Fab fragments on desipramine pharmacokinetics in the rat in vivo and in the isolated, perfused liver.
Keyler DE; Le Couteur DG; Pond SM; St Peter JV; Pentel PR
J Pharmacol Exp Ther; 1995 Mar; 272(3):1117-23. PubMed ID: 7891324
[TBL] [Abstract][Full Text] [Related]
16. Fab antibodies capable of blocking T cells by competitive binding have the identical specificity but a higher affinity to the MHC-peptide-complex than the T cell receptor.
Neumann F; Sturm C; Hülsmeyer M; Dauth N; Guillaume P; Luescher IF; Pfreundschuh M; Held G
Immunol Lett; 2009 Aug; 125(2):86-92. PubMed ID: 19524620
[TBL] [Abstract][Full Text] [Related]
17. The world of beta- and gamma-peptides comprised of homologated proteinogenic amino acids and other components.
Seebach D; Beck AK; Bierbaum DJ
Chem Biodivers; 2004 Aug; 1(8):1111-239. PubMed ID: 17191902
[TBL] [Abstract][Full Text] [Related]
18. Renal metabolism of 3'-iodohippuryl N(epsilon)-maleoyl-L-lysine (HML)-conjugated Fab fragments.
Fujioka Y; Arano Y; Ono M; Uehara T; Ogawa K; Namba S; Saga T; Nakamoto Y; Mukai T; Konishi J; Saji H
Bioconjug Chem; 2001; 12(2):178-85. PubMed ID: 11312678
[TBL] [Abstract][Full Text] [Related]
19. Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering.
Humphreys DP; Heywood SP; Henry A; Ait-Lhadj L; Antoniw P; Palframan R; Greenslade KJ; Carrington B; Reeks DG; Bowering LC; West S; Brand HA
Protein Eng Des Sel; 2007 May; 20(5):227-34. PubMed ID: 17452434
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides.
Duchardt F; Fotin-Mleczek M; Schwarz H; Fischer R; Brock R
Traffic; 2007 Jul; 8(7):848-66. PubMed ID: 17587406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
